Generic Drugs Marketing Pharma Companies 
Pharmaceutical Technology
DECEMBER 15, 2022
Inflation at its current levels poses a major threat to generics production and usage. Since the summer, generics makers have been signalling that additional support for help with rising costs is required to keep generics production viable. Inflation can damage production viability of European drugs.
World of DTC Marketing
APRIL 12, 2021
QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. Why would a pharma company take risks like these?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JUNE 22, 2022
PBMs, insurers, pharma companies, and hospitals don’t want to give up their profits even if it’s better for the general population. Then there is the cost of generic drugs. billion in 2020 if it had purchased 77 of 89 drugs from Cuban’s firm.
Camargo
NOVEMBER 11, 2020
When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning.
World of DTC Marketing
JULY 27, 2022
Huge Insurance companies continue shifting costs onto patients, with disastrous consequences for individuals’ health and society. Pharma companies have very little control over patients’ prices for their Rxs. Insurers have started coming after the co-pay coupons that many drug companies issue directly to patients.
Pharmaceutical Technology
FEBRUARY 24, 2023
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact.
World of DTC Marketing
JANUARY 31, 2021
So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). I have worked with and stayed in contact with some R&D people within pharma and they have a different answer. In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1
Expert insights. Personalized for you.
246 
Let's personalize your content